Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia

Journal of Lipid Research

Volumn 44, Issue 1, 2003, Pages 212-217

  Blom, Dirk J ^a   Byrnes, Pamela ^a   Jones, Sheena ^a   Marais, A David ^a  

^a NONE

Author keywords

Apolipoprotein E; Method; Remnants; Type III hyperlipidemia

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

AGAR GEL ELECTROPHORESIS; AREA UNDER THE CURVE; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DENATURATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; LABORATORY DIAGNOSIS; LIPID ANALYSIS; LIPID TRANSPORT; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCREENING; ULTRACENTRIFUGATION; VIDEODENSITOMETRY;

EID: 0037237989     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.D200013-JLR200     Document Type: Article

References (34)

1. Mahley, R. W., and S. Rail. 1995. Type III Hyperlipoproteinemia (Dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Basis of Inherited Disease. A. Scriver, W. Beadet, S. Sly, and D.Valle, editors. McGraw-Hill, New York. 1953-1980.
2. Mahley, R. W., and Z. Ji. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1-16.
3. Mahley, R. W., Y. Huang, and S. Rall. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries and paradoxes. J. Lipid Res. 40: 1933-1949.
4. Brewer, H., L. Zech, R. Gregg, D. Schwartz, and E. Schaefer. 1983. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology and treatment. Ann. Intern. Med. 98: 623-640.
5. Morganroth, J., R. Levy, and D. S. Fredrickson. 1975. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann. Intern. Med. 82: 158-174.
6. Mabuchi, H., H. Itoh, K. Kajinami, T. Wakasugi, J. Koizumi, R. Tadeka, and C. Asagami. 1989. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency. Metabolism. 38: 115-119.
7. Schaefer, E., R. Gregg, G. Ghiselli, T. Forte, J. L. Ordovas, L. Zech, and B. Brewer. 1986. Familial Apolipoprotein E Deficiency. J. Clin. Invest. 78: 1206-1219.
8. Connelly, P. 1999.The role of hepatic lipase in lipoprotein metabolism. Clin. Chim. Acta. 286: 243-255.
9. Utermann, G., M. Jaeschke, and J. Menzel. 1975. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett. 56: 352-355.
10. Zannis, V. I., J. L. Breslow, G. Utermann, R. W. Mahley, K. H. Weisgraber, R.J. Havel, J. L. Goldstein, M. S. Brown, G. Schonfeld, W. Hazzard, and C. Blum. 1982. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J. Lipid Res. 23: 911-914.
11. Weisgraber, K. H., T. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein-receptor binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
12. Civeira, F., A. Cenarro, J. Ferrando, J. Puzo, A. L. Garcia-Otin, P. Mozas, and M. Pocovi. 1999. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am. Heart J. 138: 156-162.
13. Illingworth, D. R., and J. P. O'Malley. 1990. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism. 39: 403-409.
14. Stuyt, P. M. and A. Van t' Laar. 1983. Clinical features of type III hyperlipoproteinaemia. Neth. J. Med. 26: 104-111.
15. Fredrickson, D. S., R. Levy, and R. Lees. 1967. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N. Eng. J. Med. 276: 215-224.
16. Masket, B. H., R. Levy, and D. S. Fredrickson. 1973. The use of polyacrylamide gel electrophoresis in differentiating Type III hyperlipoproteinemia. J. Lab. Clin. Med. 81: 794-802.
17. Fredrickson, D. S., J. Morganroth, and R. Levy. 1975. Type III hyperlipoproteinemia; an analysis of two contemporary definitions. Ann. Intern. Med. 82: 150-157.
18. Albers, J.J. R. G. Warnick, and W. Hazzard. 1977. Type III hyperlipoproteinemia: a comparative study of current diagnostic techniques. Clin. Chim. Acta. 75: 193-204.
19. Papadopoulos, N. M., and P. N. Herbert. 1977. The β-lipoprotein doublet in type III hyperlipoproteinemia. Clin. Chem. 23: 978-981.
20. Seidel, D., and H. Greten. 1970. Hyperlipoproteinämie-typ III-eine M6glichkeit zur imnmnologischen diagnostik. Clin. Chim. Acta. 30: 31-36.
21. Wieland, H., and D. Seidel. 1973. Improved techniques for assessment of serum lipoprotein patterns. ii. rapid methods for diagnosis of type III hyperlipoproteinemia without ultracentrifugation. Clin. Chem. 19: 1139-1141.
22. Wikinski, R. L. W., L. E. Schreier, and S. B. Rosental. 1991. New method for isolating and quantifying intermediate and β-very-lowdensity lipoprotein cholesterol. Clin. Chem. 37: 1913-1916.
23. Hazzard, W., D. J. Porte, and E. L. Bierman. 1972. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type III hyperlipoproteinemia). Metabolism. 21: 1009-1019.
24. Mishkel, M. A., D. J. Nazir, and S. Crowther. 1975. A longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinaemia. Clin. Chim. Acta. 58: 121-136.
25. Wang, T., K. Nakajima, E. T. Leary, G. R. Warnick, J. S. Cohn, P. N. Hopkins, L. L. Wu, D. D. Cilla, J. Zhong, and R.J. Havel. 1999. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia. Clin. Chem. 45: 1981-1987.
26. Hixson, J. E., and D. T. Vernier. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31: 545-548.
27. Dormans, T. P.J., D. W. Swinkels,J. de Graaf, J. C. M. Hendriks, A. Stalenhoef, and P. Demacker. 1991. Single-spin density -gradient ultracentrifugation vs. gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin. Chem. 37: 853-858.
28. Blance, P.J., E. L. Gong, T. Forte, and A. V. Nichols. 1981. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta. 665: 408-419.
29. Gambert, P., C. Bouzerand-Gambert, A. Athias, M. Farnier, and C. Lallemant. 1990. Human low density lipoprotein subfractions separated by gradient gel electrophoresis: composition, distribution, and alterations induced by cholesteryl ester transfer protein. J. Lipid Res. 31: 1199-1210.
30. Austin, M. A., J. C. Breslow, C. H. Hennekens, J. E. Buring, W. G. Willet, and R. M. Kraus. 1988. Low-density lipoprotein subclass pattern and risk of myocardial infarction J. Amer. Med. Assoc. 260: 1917-1921
31. de Villiers, W.J.S., D. R. van der Westhuyzen, G. A. Coetzee, H. E. Henderson, and A. D. Marais. 1997. The apolipoproteinE2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler. Throm. Vasc. Biol. 17: 865-872.
32. Lindgren, F. T., L. C.Jensen, and F. T. Hatch. 1972.The isolation and quantitative analysis of serum lipoproteins in blood lipids and lipoproteins: quantitation, composition and metabolism. G.J. Nelson, editor. John Wiley and Sons Inc., New York. 181-207.
33. Hsia, S. H., P. Connelly, and R. Hegele. 1995. Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia. J. Investig. Med. 43: 187-195.
34. Chew, M. Y., J. M. Gutman, and J. Green. 1978. A case of Type III hyperlipoproteinaemia studied by acrylamide gel gradient electrophoresis. J. Clin. Path. 31: 599-601.